When was PTC Therapeutics founded?

PTC Therapeutics was founded in 1998 and raised its 1st funding round 3 years after it was founded.

Where is PTC Therapeutics located?

PTC Therapeutics is headquartered in South Plainfield, United States.

Who is the current CEO of PTC Therapeutics?

Stuart Peltz of PTC Therapeutics.

How many employees does PTC Therapeutics have?

As of Jun 30, 2026, the latest employee count at PTC Therapeutics is 1158.

Is PTC Therapeutics a funded company?

PTC Therapeutics is a funded company, having raised a total of $248M across 24 funding rounds to date. The company's 1st funding round was a $***** Series D round, raised on Sep 19, 2001.

When was the latest funding round of PTC Therapeutics?

PTC Therapeutics' latest funding was a $***** Post IPO round on May 16, 2023, with participation from 0 investor.

What is the annual revenue of PTC Therapeutics?

Annual revenue of PTC Therapeutics is more than $1B as on Dec 31, 2025

Where does PTC Therapeutics rank among its competitors?

PTC Therapeutics ranks 6th amongst 3082 active competitors, of which 1050 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was BridgeBio, which secured $200M in Apr, 2024.

Who are the top competitors of PTC Therapeutics?

PTC Therapeutics' top competitors include Jazz Pharmaceuticals, BridgeBio and Alnylam. Among them, BridgeBio secured the most recent funding round in April, 2024.

PTC Therapeutics - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Developer of small molecule drugs for the treatment of rare diseases. The company's lead product Ataluren is an orally administered small-molecule drug for the treatment of cystic fibrosis and Duchenne muscular dystrophy caused by nonsense mutations. Also, developing anticancer and antibacterial drugs.

Website: www.ptcbio.com/
Social
Email ID: *****@ptcbio.com
Phone Number: +1 **********

Key Metrics

Founded Year

1998

Location

South Plainfield, United States

Stage

Public

Total Funding

$248M in 24 rounds

Latest Funding Round

Post IPO, May 16, 2023, $*****

Investors

Credit Suisse First Boston & 29 more

Ranked

6^th among 3082 active competitors

Annual Revenue

$1B+ as on Dec 31, 2025

Employee Count

1,158 as on Jun 30, 2026

Investment & Acquisitions

ClearPoint Neuro & 3 more

Similar Companies

Jazz Pharmaceuticals & 867 more

Exit Details

Public

View PTC Therapeutics' full profile

PTC Therapeutics is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Ptc Therapeutics, Inc. CIN: 1070081 , United States, Active	Mar 30, 1998	$1B+ (As on Dec 31, 2025)	713 (As on Dec 31, 2020)	-
PTC THERAPEUTICS, LIMITED CIN: 7965055 , Belgium, Active	Feb 23, 2012	-	995 (As on Dec 31, 2023)	-
Ptc Therapeutics, Inc. CIN: 32065646773 , United States, Active	Dec 11, 2017	-	-	-

PTC Therapeutics got listed on Jun 20, 2013.

Click here to take a look at PTC Therapeutics's IPO in detail

PTC Therapeutics has raised a total funding of $248M over 24 rounds. Its first funding round was on Sep 19, 2001. PTC Therapeutics has 30 institutional investors.

Here is the list of recent funding rounds of PTC Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 16, 2023	8615191	Post IPO	4388951	2468269	1220057	1503725
May 14, 2020	6090610	Post IPO	1263751	9815274	4961620	6988699
Sep 18, 2019	7961850	Post IPO	5433472	1561227	3720364	5312291

Access funding benchmarks and valuations. Sign up today!

View details of PTC Therapeutics's funding rounds and investors

The founders of PTC Therapeutics is Stuart Peltz.

Here are the details of PTC Therapeutics' key team members:

Stuart Peltz: Founder & CEO of PTC Therapeutics.

View details of PTC Therapeutics's Founder profiles and Board Members

PTC Therapeutics' employee count trend

PTC Therapeutics has 1,158 employees as of Jun 26. Here is PTC Therapeutics's employee count trend over the years:

Employee count trend for PTC Therapeutics

Uncover PTC Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of PTC Therapeutics include Jazz Pharmaceuticals, BridgeBio and Alnylam. Here is the list of Top 10 competitors of PTC Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BridgeBio 2015, Palo Alto (United States), Public	Developer of therapeutics for the treatment of genetic diseases	$434M	Viking Global Investors, KKR & 20 others	81/100
3rd	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Bellevue Healthcare Trust ... & 13 others	79/100
4th	Alexion 1992, Zurich (Switzerland), Acquired	Developer of therapies for patients with devastating and rare diseases	$133M	Allen & Company, Invesco & 9 others	79/100
5th	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
6th	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Brookside Capital ... & 28 others	77/100
7th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 17 others	75/100
8th	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	73/100
9th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	72/100
10th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Nextech Invest, Third Rock Ventures & 20 others	72/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on PTC Therapeutics's competitors? Click here to see the top ones

PTC Therapeutics has made 2 investments in companies including ClearPoint Neuro and MRI Interventions. PTC Therapeutics has also acquired 2 companies including Censa Pharmaceuticals and Agilis Biotherapeutics.

Here is the list of investments & acquisitions:

Filter this list

Date of Investment/Acquisition	Type	Company Name	Founded Year	Location
Dec 29, 2020	Investments	ClearPoint Neuro	1998	Irvine (United States)
May 06, 2020	Acquisition	Censa Pharmaceuticals	2015	Cambridge (United States)
Jan 13, 2020	Investments	MRI Interventions	1998	Irvine (United States)

Want to know more about where corporates are investing? Sign up today!

Here is the latest report on PTC Therapeutics's sector:

Free

Neurology - Sector Report

Edition: June, 2026 (65 Pages)

View all reports related to PTC Therapeutics

Media has covered PTC Therapeutics for a total of 24 events in the last 1 year, 13 of them have been about company updates and 1 about people movement.